Frost A, Mohla C, Luban N, Campos J; International Conference on AIDS.
Int Conf AIDS. 1989 Jun 4-9; 5: 325 (abstract no. T.B.P.230).
George Washington University Hospital, Washington, DC, USA
OBJECTIVE: To compare the performance of the HIV Recombinant Antigen Neutralization Assay (RANA) (Ortho Diagnostic Systems, Raritan, NJ, USA) and the HIV Western blot Kit (WB) (DuPont Company, Wilmington, DE, USA) as confirmatory tests of HIV ELISA repeatedly reactive sera from high-risk children. METHODS: RANA uses a pool of recombinant core (p24), polymerase (p31) and envelope (gp41) antigens for neutralization of HIV antibodies in ELISA positive sera. Dilutions of reactive sera were added to the antigen mixture and incubated for 16-18 hours at 37 degrees C. The ELISA reactivity (Abbott HIV EIA, Abbott Laboratories, North Chicago, IL, USA) of each neutralized serum was determined and compared to an unneutralized control. A reduction in absorbance by greater than or equal to 40% constituted a positive test. WB was performed and interpreted according to the manufacturer's instructions. RESULTS: All 34 study sera were positive by RANA (mean neutralization 72%), and 25 (74%) were positive by WB. Nine sera (26%) yielded indeterminate WB results. Of the nine, 6 were tested for HIV antigen (Abbott HTLV III Antigen EIA) and 4 were positive. None of the HIV ELISA repeatedly reactive sera collected from our high-risk population during the study period was RANA or WB negative. CONCLUSION: RANA is a sensitive, objectively interpreted confirmatory test of HIV ELISA seropositivity in high-risk children.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Blotting, Western
- Chicago
- Child
- Enzyme-Linked Immunosorbent Assay
- HIV
- HIV Antibodies
- HIV Antigens
- HIV Infections
- HIV Seronegativity
- HIV Seropositivity
- Humans
- Immunoenzyme Techniques
- immunology
- organization & administration
Other ID:
UI: 102177483
From Meeting Abstracts